Pharmaron
Pharmaron offers Biologics characterization, PK/TK, immunogenicity and biomarkers. This is the analytical service business of an integrated CRO/CDMO.
Corporate information
- Company entity
- Pharmaron
- Headquarters / principal office
- Headquarters city not independently verified; see the country/network tags.
- Founded
- 2004 ↗
- Ownership / capital status
- Publicly tradedPublicly listed; see issuer disclosures ↗
- Official corporate reference
- https://pharmaron.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-09-02 · 零息可转换债券 · 本金21.8亿元人民币（美元结算） ↗
债券本金而非Equity Financing或净募集款；2027年到期。
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
The company explicitly supports PROTACs, hydrophobic tags, and molecular glues through FFS, FTE, and integrated discovery models, including target engagement, ubiquitination, proteasome dependence, and bioanalysis.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Targeted Protein Degradation I Pharmaron CRO Services
- About Pharmaron
- Pharmaron company page
- Pharmaron issuer announcement: completion convertible bonds